Study design (if review, criteria of inclusion for studies)
Randomised, cross-over study.
Participants
10 CF patients(age 9 to 21 years).
Interventions
Single dose 20 mg sodium cromoglycate and beta agonist with: 1. ultrasonic nebuliser; 2. jet nebuliser.
Outcome measures
Treatment time. Residual volume of medication in nebuliser. Excreted sodium cromoglycate in urine up to 12 hours post-dose
Main results
Using the ultrasonic nebulizer, the amount of SCG excreted in urine was significantly greater than that after inhalation with the jet nebulizer (1.43 +/- 0.47 mg vs. 1.04 +/- 0.47 mg; p = 0.002), despite the larger residual volume in the ultrasonic nebulizer. The absorption half-life for SCG following ultrasonic nebulization was significantly shorter when compared with jet nebulization (84 +/- 14 min vs. 101 +/- 19 min; p = 0.005), being suggestive of a more peripheral deposition. Furthermore, an inverse relationship was found between absorption half-life and FEV(1) (% pred.) (r = -0.655, p = 0.04) or MMEF(75/25) (% pred.) (r = -0.844, p = 0.031), but only with the ultrasonic nebulizer.
Authors' conclusions
The ultrasonic nebulizer tested when used for inhalation in CF patients was found to be at least equivalent to the jet nebulizer.
Keywords: Inhalation OR nebulised; non pharmacological intervention - devices OR physiotherapy; nebuliser; Adrenergic beta-Agonists; Bronchodilator Agents; Respiratory System Agents; pharmacological_intervention;